 |
|
Outcome Measures of Disease Severity in Atopic Eczema
Carolyn Charman, BM, BCh, MRCP;
Hywel Williams, PhD, FRCP
Arch Dermatol. 2000;136:763-769.
Background An essential component of evidence-based medicine is the use of valid and reliable outcome measures in clinical trials. There is much confusion in the field of atopic eczema regarding how to best measure disease severity objectively.
Objective To establish the extent to which existing objective clinical scales for atopic eczema have been tested for validity, reliability, sensitivity to change, and acceptability.
Design An electronic bibliographic search was performed for published data on all currently available named atopic eczema scales.
Results Thirteen scales were identified in total. Data on construct or criterion validity were available for 10 scales. Only 5 scales had been tested for reliability (interobserver variability, intraobserver variability, or internal consistency). Data on responsiveness to change were available for 8 scales. An estimated time to administer the measure had been given for 3 scales. The only severity scale for which published data could be found on validity, reliability, sensitivity, and acceptability testing was the Severity Scoring of Atopic Dermatitis index, although problems occurred with interobserver variation of the index.
Conclusion The rapidly increasing number of severity scales for atopic eczema, many of which have been inadequately tested, has made the interpretation of patient outcomes confusing, and comparison of results between studies almost impossible. Consensus among clinicians and researchers on the use of severity scales for atopic eczema should be based on evidence of adequate validity, reliability, sensitivity to change, and ease of use.
From the Department of Dermatology, Queen's Medical Centre, Nottingham, England.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Giving "Scale" New Meaning in Dermatology: Measurement Matters
Mary-Margaret Chren
Arch Dermatol. 2000;136(6):788-790.
EXTRACT
| FULL TEXT
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2000;136(6):811-812.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
What is meant by a "flare" in atopic dermatitis?: a systematic review and proposal.
Langan et al.
Arch Dermatol 2006;142:1190-1196.
ABSTRACT
| FULL TEXT
Measuring Atopic Eczema Severity Visually: Which Variables Are Most Important to Patients?
Charman et al.
Arch Dermatol 2005;141:1146-1151.
ABSTRACT
| FULL TEXT
Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials
Ashcroft et al.
BMJ 2005;330:516.
ABSTRACT
| FULL TEXT
The Patient-Oriented Eczema Measure: Development and Initial Validation of a New Tool for Measuring Atopic Eczema Severity From the Patients' Perspective
Charman et al.
Arch Dermatol 2004;140:1513-1519.
ABSTRACT
| FULL TEXT
Parametric Modeling of Narrowband UV-B Phototherapy for Vitiligo Using a Novel Quantitative Tool: The Vitiligo Area Scoring Index
Hamzavi et al.
Arch Dermatol 2004;140:677-683.
ABSTRACT
| FULL TEXT
The Objective Severity Assessment of Atopic Dermatitis Score: An Objective Measure Using Permeability Barrier Function and Stratum Corneum Hydration With Computer-Assisted Estimates for Extent of Disease
Sugarman et al.
Arch Dermatol 2003;139:1417-1422.
ABSTRACT
| FULL TEXT
"Objective" Measures of Atopic Dermatitis Severity: In Search of the Holy Grail
Williams
Arch Dermatol 2003;139:1490-1492.
FULL TEXT
Applying Trial Evidence Back to the Patient
Williams
Arch Dermatol 2003;139:1195-1200.
FULL TEXT
Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema
Thomas et al.
BMJ 2002;324:768-768.
ABSTRACT
| FULL TEXT
Giving "Scale" New Meaning in Dermatology: Measurement Matters
Chren
Arch Dermatol 2000;136:788-790.
FULL TEXT
|
